Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Digestim is a multi-enzyme digestive aid developed and marketed by the Russian pharmaceutical company Avva Rus. It is formulated as a complex of digestive enzymes derived from microbial sources, including amylase, protease, lipase, cellulase, and lactase. These enzymes facilitate the breakdown of macronutrients—carbohydrates, proteins, and fats—as well as plant fiber and lactose, assisting in the management of digestive discomfort, bloating, and functional dyspepsia. In the Russian market, it is registered as a dietary supplement (BAA) and is positioned as a natural alternative to traditional animal-derived pancreatin medications, particularly for individuals with enzyme deficiencies or those consuming hard-to-digest foods.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Digestim.